KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) EBT (2016 - 2025)

Boston Scientific's EBT history spans 17 years, with the latest figure at $700.0 million for Q4 2025.

  • For Q4 2025, EBT rose 19.66% year-over-year to $700.0 million; the TTM value through Dec 2025 reached $3.4 billion, up 48.33%, while the annual FY2025 figure was $3.4 billion, 48.33% up from the prior year.
  • EBT for Q4 2025 was $700.0 million at Boston Scientific, down from $939.0 million in the prior quarter.
  • Across five years, EBT topped out at $941.0 million in Q2 2025 and bottomed at $119.0 million in Q4 2021.
  • The 5-year median for EBT is $463.5 million (2021), against an average of $493.5 million.
  • The largest YoY upside for EBT was 1377.27% in 2021 against a maximum downside of 61.24% in 2021.
  • A 5-year view of EBT shows it stood at $119.0 million in 2021, then surged by 232.77% to $396.0 million in 2022, then rose by 27.53% to $505.0 million in 2023, then increased by 15.84% to $585.0 million in 2024, then rose by 19.66% to $700.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's EBT are $700.0 million (Q4 2025), $939.0 million (Q3 2025), and $941.0 million (Q2 2025).